West Pharmaceutical Services, Inc. (NYSE:WST) Shares Sold by CIBC Private Wealth Group LLC

CIBC Private Wealth Group LLC lessened its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WSTFree Report) by 2.0% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 9,457 shares of the medical instruments supplier’s stock after selling 193 shares during the quarter. CIBC Private Wealth Group LLC’s holdings in West Pharmaceutical Services were worth $3,330,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the business. NEOS Investment Management LLC lifted its position in shares of West Pharmaceutical Services by 163.8% during the fourth quarter. NEOS Investment Management LLC now owns 1,965 shares of the medical instruments supplier’s stock worth $692,000 after purchasing an additional 1,220 shares in the last quarter. CWA Asset Management Group LLC acquired a new stake in shares of West Pharmaceutical Services during the fourth quarter worth about $250,000. APG Asset Management US Inc. acquired a new stake in shares of West Pharmaceutical Services during the fourth quarter worth about $88,227,000. Evoke Wealth LLC acquired a new stake in shares of West Pharmaceutical Services during the fourth quarter worth about $7,770,000. Finally, Treasurer of the State of North Carolina lifted its position in shares of West Pharmaceutical Services by 2.1% during the fourth quarter. Treasurer of the State of North Carolina now owns 35,213 shares of the medical instruments supplier’s stock worth $12,399,000 after purchasing an additional 724 shares in the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

Wall Street Analysts Forecast Growth

WST has been the topic of a number of recent research reports. KeyCorp upped their target price on shares of West Pharmaceutical Services from $440.00 to $470.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 13th. StockNews.com lowered shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research note on Friday, February 16th. Finally, UBS Group cut their target price on shares of West Pharmaceutical Services from $400.00 to $375.00 and set a “neutral” rating on the stock in a research note on Friday, February 16th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, West Pharmaceutical Services has an average rating of “Moderate Buy” and a consensus price target of $435.20.

Check Out Our Latest Stock Analysis on West Pharmaceutical Services

Insider Buying and Selling at West Pharmaceutical Services

In other West Pharmaceutical Services news, CAO Chad Winters sold 815 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $358.82, for a total value of $292,438.30. Following the transaction, the chief accounting officer now directly owns 1,309 shares in the company, valued at $469,695.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CAO Chad Winters sold 815 shares of the stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $358.82, for a total value of $292,438.30. Following the completion of the sale, the chief accounting officer now directly owns 1,309 shares of the company’s stock, valued at $469,695.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Eric Mark Green sold 66,000 shares of the stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $366.65, for a total value of $24,198,900.00. Following the completion of the sale, the chief executive officer now directly owns 152,908 shares of the company’s stock, valued at $56,063,718.20. The disclosure for this sale can be found here. 0.53% of the stock is currently owned by insiders.

West Pharmaceutical Services Stock Performance

Shares of West Pharmaceutical Services stock opened at $314.76 on Friday. The firm has a market capitalization of $22.93 billion, a P/E ratio of 41.53, a P/E/G ratio of 5.57 and a beta of 1.01. West Pharmaceutical Services, Inc. has a 52 week low of $310.42 and a 52 week high of $415.73. The company has a quick ratio of 1.95, a current ratio of 2.61 and a debt-to-equity ratio of 0.03. The firm’s 50 day moving average is $361.29 and its two-hundred day moving average is $362.79.

West Pharmaceutical Services (NYSE:WSTGet Free Report) last announced its quarterly earnings results on Thursday, April 25th. The medical instruments supplier reported $1.56 EPS for the quarter, beating the consensus estimate of $1.29 by $0.27. The company had revenue of $695.40 million for the quarter, compared to analyst estimates of $670.62 million. West Pharmaceutical Services had a net margin of 19.42% and a return on equity of 20.57%. The firm’s revenue was down 3.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.98 earnings per share. Research analysts forecast that West Pharmaceutical Services, Inc. will post 7.76 EPS for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, August 7th. Shareholders of record on Wednesday, July 31st will be paid a $0.20 dividend. The ex-dividend date of this dividend is Wednesday, July 31st. This represents a $0.80 annualized dividend and a yield of 0.25%. West Pharmaceutical Services’s dividend payout ratio is currently 10.55%.

About West Pharmaceutical Services

(Free Report)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

Featured Articles

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WSTFree Report).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.